To further test EMBER in a real world clinical setting, we used gene expression data from the POETIC trial29, a window trial, which evaluated tumor response to the aromatase inhibitors letrozole or anastrozole in postmenopausal ER+ BC patients using Ki67 index as endpoint. The gene discussed is ESR1; the disease is breast cancer.